Predict your next investment

HEALTHCARE | Drug Discovery
esperion.com

See what CB Insights has to offer

Founded Year

1998

Stage

IPO | IPO

Total Raised

$122M

Date of IPO

6/26/2013

Market Cap

0.21B

Stock Price

7.77

About Esperion Therapeutics

Esperion Therapeutics discovers and develops therapies for the treatment of cardiometabolic diseases. The company's lead product candidate, ETC-1002, is an AMP kinase activator and ATP citrate lyase inhibitor that is being evaluated in multiple Phase 2 clinical trials for the treatment of hypercholesterolemia and other cardiometabolic risk factors. Esperion intends to commercialize first-in-class therapies focused on enhancing lipid regulation, addressing statin intolerance and improving overall cardiometabolic health.In June 2013, Esperion Therapeutics went public with a valuation of $197 million.

Esperion Therapeutics Headquarter Location

3891 Ranchero Dr Suite 150

Ann Arbor, Michigan, 48108,

United States

734-332-0506

Latest Esperion Therapeutics News

Implied Volatility Surging for Esperion Therapeutics (ESPR) Stock Options

Nov 19, 2021

Investors need to pay close attention to Esperion Therapeutics (ESPR) stock based on the movements in the options market lately. This story originally appeared on Zacks Investors in Esperion Therapeutics, Inc. ESPR need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 21, 2022 $22.50 Call had some of the highest implied volatility of all equity options today. Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Esperion Therapeutics shares, but what is the fundamental picture for the company? Currently, Esperion Therapeutics is a Zacks Rank #3 (Hold) in the Medical - Drugs industry that ranks in the Bottom 41% of our Zacks Industry Rank. Over the last 60 days, one analyst has increased the earnings estimate for the current quarter, while three have dropped their estimates. The net effect has widened our Zacks Consensus Estimate for the current quarter from a loss of $2.34 per share to a loss of $2.74 in that period. Given the way analysts feel about Esperion Therapeutics right now, this huge implied volatility could mean there’s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected. Looking to Trade Options? Check out the simple yet high-powered approach that Zacks Executive VP Kevin Matras has used to close recent double and triple-digit winners. In addition to impressive profit potential, these trades can actually reduce your risk.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Esperion Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Esperion Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Esperion Therapeutics Patents

Esperion Therapeutics has filed 32 patents.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Combination drugs
  • Diabetes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/16/2016

9/14/2021

Statins, Hepatotoxins, Combination drugs, Fluoroarenes, Hypolipidemic agents

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

3/16/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/14/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Statins, Hepatotoxins, Combination drugs, Fluoroarenes, Hypolipidemic agents

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Esperion Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Esperion Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.